LLY Quote, Financials, Valuation and Earnings

Moderna has a net margin of 21.68% compared to Eli Lilly and's net margin of -907.48%. Eli Lilly and's return on equity of 78.25% beat Moderna's return on equity of -29.23%.

Eli Lilly and has a consensus price target of $951.98, signalling upside risk potential of 17.88%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 83.04%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.404, which suggesting that the stock is 59.63% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.69%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Moderna quarterly revenues of $107M. Eli Lilly and's net income of $2.8B is higher than Moderna's net income of -$971M. Notably, Eli Lilly and's price-to-earnings ratio is 65.71x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 14.89x versus 3.22x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 21.68% compared to Eli Lilly and's net margin of 26.7%. Eli Lilly and's return on equity of 78.25% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Eli Lilly and has a consensus price target of $951.98, signalling upside risk potential of 17.88%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 39.13%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.404, which suggesting that the stock is 59.63% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.69%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Eli Lilly and's net income of $2.8B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Eli Lilly and's price-to-earnings ratio is 65.71x while Regeneron Pharmaceuticals's PE ratio is 13.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 14.89x versus 4.23x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 21.68% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 78.25% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $951.98, signalling upside risk potential of 17.88%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 234.8%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.404, which suggesting that the stock is 59.63% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.236%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.69%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $2.8B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Eli Lilly and's price-to-earnings ratio is 65.71x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 14.89x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 21.68% compared to Eli Lilly and's net margin of 23.33%. Eli Lilly and's return on equity of 78.25% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Eli Lilly and has a consensus price target of $951.98, signalling upside risk potential of 17.88%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 10.91%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Eli Lilly and has a beta of 0.404, which suggesting that the stock is 59.63% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.69%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Eli Lilly and's net income of $2.8B is higher than Vertex Pharmaceuticals's net income of $646.3M. Notably, Eli Lilly and's price-to-earnings ratio is 65.71x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 14.89x versus 10.52x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.